VIRAX BIOLABS GROUP LTD (VRAX) Stock Price, Quote, News and Overview
NASDAQ:VRAX - Nasdaq - KYG9495L1251 - Common Stock - Currency: USD
VRAX Quote, Performance and Key Statistics
1.36
-0.11 (-7.48%)
The current stock price of VRAX is 1.36 USD. In the past month the price decreased by -18.56%. In the past year, price increased by 52.81%.
VRAX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| MCK | MCKESSON CORP | 21.93 | 80.16B | ||
| COR | CENCORA INC | 17.7 | 48.72B | ||
| CAH | CARDINAL HEALTH INC | 16.48 | 30.78B | ||
| HSIC | HENRY SCHEIN INC | 15.08 | 8.87B | ||
| PDCO | PATTERSON COS INC | 13.48 | 2.75B | ||
| AHCO | ADAPTHEALTH CORP | 17.4 | 1.40B | ||
| OMI | OWENS & MINOR INC | 6.41 | 751.05M | ||
| AHG | AKSO HEALTH GROUP | N/A | 538.41M | ||
| COSM | COSMOS HEALTH INC | N/A | 11.82M | ||
| ATPC | AGAPE ATP CORP | N/A | 4.35M |
Related stock screener links
About VRAX
Company Profile
Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The firm is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Company Info
VIRAX BIOLABS GROUP LTD
Biocity Glasgow, Bo'ness Road, Newhouse
London GB
Employees: 17
Company Website: https://www.viraxbiolabs.com
Investor Relations: https://ir.viraxbiolabs.com/
Phone: 4402077887414
VIRAX BIOLABS GROUP LTD / VRAX FAQ
What is the stock price of VIRAX BIOLABS GROUP LTD today?
The current stock price of VRAX is 1.36 USD. The price decreased by -7.48% in the last trading session.
What is the ticker symbol for VIRAX BIOLABS GROUP LTD stock?
The exchange symbol of VIRAX BIOLABS GROUP LTD is VRAX and it is listed on the Nasdaq exchange.
On which exchange is VRAX stock listed?
VRAX stock is listed on the Nasdaq exchange.
What is VIRAX BIOLABS GROUP LTD worth?
VIRAX BIOLABS GROUP LTD (VRAX) has a market capitalization of 5.90M USD. This makes VRAX a Nano Cap stock.
How many employees does VIRAX BIOLABS GROUP LTD have?
VIRAX BIOLABS GROUP LTD (VRAX) currently has 17 employees.
What are the support and resistance levels for VIRAX BIOLABS GROUP LTD (VRAX) stock?
VIRAX BIOLABS GROUP LTD (VRAX) has a resistance level at 1.74. Check the full technical report for a detailed analysis of VRAX support and resistance levels.
Is VIRAX BIOLABS GROUP LTD (VRAX) expected to grow?
The Revenue of VIRAX BIOLABS GROUP LTD (VRAX) is expected to grow by 477.17% in the next year. Check the estimates tab for more information on the VRAX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VIRAX BIOLABS GROUP LTD (VRAX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VRAX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VRAX, evaluating the profitability, health, valuation and growth aspects
- VIRAX BIOLABS GROUP LTD (VRAX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VIRAX BIOLABS GROUP LTD (VRAX) Sales and EPS estimates to see what analysts future expectations are.
- VIRAX BIOLABS GROUP LTD (VRAX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VIRAX BIOLABS GROUP LTD (VRAX) Insider and Institutional Ownership to learn about the owners and their transactions.
- VIRAX BIOLABS GROUP LTD (VRAX) Stock Chart to make your own analysis
- VIRAX BIOLABS GROUP LTD (VRAX) Latest news and press-releases to stay up to date.
Does VIRAX BIOLABS GROUP LTD (VRAX) stock pay dividends?
VRAX does not pay a dividend.
When does VIRAX BIOLABS GROUP LTD (VRAX) report earnings?
VIRAX BIOLABS GROUP LTD (VRAX) will report earnings on 2022-12-13, before the market open.
What is the Price/Earnings (PE) ratio of VIRAX BIOLABS GROUP LTD (VRAX)?
VIRAX BIOLABS GROUP LTD (VRAX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.6).
What is the Short Interest ratio of VIRAX BIOLABS GROUP LTD (VRAX) stock?
The outstanding short interest for VIRAX BIOLABS GROUP LTD (VRAX) is 4.45% of its float. Check the ownership tab for more information on the VRAX short interest.
VRAX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to VRAX. When comparing the yearly performance of all stocks, VRAX is one of the better performing stocks in the market, outperforming 86.45% of all stocks.
VRAX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to VRAX. The financial health of VRAX is average, but there are quite some concerns on its profitability.
VRAX Financial Highlights
Over the last trailing twelve months VRAX reported a non-GAAP Earnings per Share(EPS) of -2.6. The EPS increased by 34.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.69% | ||
| ROE | -76.12% | ||
| Debt/Equity | 0.06 |
VRAX Ownership and Analysts
For the next year, analysts expect an EPS growth of 68.42% and a revenue growth 477.17% for VRAX